Could a Mediterranean Diet Modulate Alzheimer’s Disease Progression? The Role of Gut Microbiota and Metabolite Signatures in Neurodegeneration
Foods,
Journal Year:
2025,
Volume and Issue:
14(9), P. 1559 - 1559
Published: April 29, 2025
Neurodegenerative
disorders
such
as
Alzheimer's
disease
(AD),
the
most
common
form
of
dementia,
represent
a
growing
global
health
crisis,
yet
current
treatment
strategies
remain
primarily
palliative.
Recent
studies
have
shown
that
neurodegeneration
through
complex
interactions
within
gut-brain
axis
largely
depends
on
gut
microbiota
and
its
metabolites.
This
review
explores
intricate
molecular
mechanisms
linking
dysbiosis
to
cognitive
decline,
emphasizing
impact
microbial
metabolites,
including
short-chain
fatty
acids
(SCFAs),
bile
acids,
tryptophan
neuroinflammation,
blood-brain
barrier
(BBB)
integrity,
amyloid-β
tau
pathology.
The
paper
highlights
major
microbiome
signatures
associated
with
disease,
detailing
their
metabolic
pathways
inflammatory
crosstalk.
Dietary
interventions
promise
in
modulating
composition,
potentially
mitigating
neurodegenerative
processes.
critically
examines
influence
dietary
patterns,
Mediterranean
Western
diets,
microbiota-mediated
neuroprotection.
Bioactive
compounds
like
prebiotics,
omega-3
polyphenols
exhibit
neuroprotective
effects
by
reducing
neuroinflammation.
Furthermore,
it
discusses
emerging
microbiome-based
therapeutic
strategies,
probiotics,
postbiotics,
fecal
transplantation
(FMT),
potential
for
slowing
progression.
Despite
these
advances,
several
knowledge
gaps
remain,
interindividual
variability
responses
need
large-scale,
longitudinal
studies.
study
proposes
an
integrative,
precision
medicine
approach,
incorporating
science
into
paradigms.
Ultimately,
cognizance
at
mechanistic
level
could
unlock
novel
avenues,
offering
non-invasive,
diet-based
strategy
managing
improving
health.
Language: Английский
From Synaptic Plasticity to Neurodegeneration: BDNF as a Transformative Target in Medicine
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(9), P. 4271 - 4271
Published: April 30, 2025
The
brain-derived
neurotrophic
factor
(BDNF)
has
become
one
of
the
cornerstones
neuropathology,
influencing
synaptic
plasticity,
cognitive
resilience,
and
neuronal
survival.
Apart
from
its
molecular
biology,
BDNF
is
a
powerful
target
for
transformative
benefit
in
precision
medicine,
leading
to
innovative
therapeutic
approaches
neurodegenerative
psychiatric
diseases
like
Alzheimer's
disease
(AD),
Parkinson's
(PD),
major
depressive
disorder
(MDD),
post-traumatic
stress
(PTSD).
Nevertheless,
clinical
applicability
obstructed
by
hurdles
delivery,
patient-specific
diversity,
pleiotropic
signaling.
Here,
we
summarize
findings
research,
including
regulatory
pathways
diagnostic/prognostic
biomarkers
integrative
approaches.
We
describe
delivery
systems,
such
as
lipid
nanoparticle-based
mRNA
therapies
CRISPR-dCas9-based
epigenetic
editing
that
bypass
obstacles
BBB
(blood-brain
barrier)
enzymatic
degradation.
recent
implementation
multiplex
panels
combining
biodynamic
indicators
with
tau
amyloid-β
signaling
markers
showcases
novel
levels
specificity
both
early
detection
potential
monitoring.
Humanized
preclinical
models
iPSC-derived
neurons
organoids
point
key
role
neurodeveloping
processes,
paralleling
advances
bridging
observation
environments.
Moreover,
tools
delivering
TrkB
activators
or
AI-based
dynamic
care
platforms
enable
tailored
scalable
treatments.
This
review
also
aims
extend
framework
used
understanding
BDNF's
relevance
traditional
situating
more
work
detailing
actions
ischemic
tissues
gut-brain
axis
context
systemic
health.
Finally,
outline
roadmap
incorporation
BDNF-centered
into
worldwide
healthcare,
highlighting
ethical
issues,
equity,
interdisciplinary
decomposition.
heralds
new
era
neuroscience
revolutionizing
brain
health
paving
way
advancement
medicine.
Language: Английский